UK markets closed
  • NIKKEI 225

    -587.59 (-1.76%)

    -117.37 (-0.71%)

    +0.26 (+0.37%)

    -2.60 (-0.13%)
  • DOW

    +62.95 (+0.17%)
  • Bitcoin GBP

    -498.21 (-1.43%)
  • CMC Crypto 200

    +3.99 (+0.45%)
  • NASDAQ Composite

    +193.28 (+1.37%)
  • UK FTSE All Share

    -2.20 (-0.05%)

Medigene AG to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

Medigene AG
Medigene AG

Martinsried/Munich, April 27, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, will be presenting at the 20th Association for Cancer Immunotherapy (CIMT) annual meeting being held on May 3-5, 2023, in Mainz.

The data to be presented will focus on Expitope 3.0, an in silico tool to identify immunogenic epitopes as suitable T cell receptor (TCR) target specificities. Moreover, Expitope 3.0 enables the comparison of expression of epitopes in various healthy tissues to predict potential cross-reactivity and off-target toxicity. Presentation of the data includes a poster as well as an oral presentation.

The abstract has been published online:

Details on the poster presentation are as follows:

Abstract and Title: “Expitope 3.0 – An Advanced in silico Webtool Empowered with Machine Learning for Enhanced pHLA Epitope Prediction and Safety Assessment”

Authors: Sebastian Karg, Andrea Coluccio, Barbara Lösch, Dolores J Schendel, Dimitri Frishmann

Abstract Number: 98

Date/Time: Wednesday, May 3rd, 2023, 3:00 pm – 5.30 pm CET

Session: Postersession I

Details on the oral presentation are as follows:

Abstract and Title: “Expitope 3.0 – An Advanced in silico Webtool Empowered with Machine Learning for Enhanced pHLA Epitope Prediction and Safety Assessment”

Speaker: Dr. Barbara Lösch

Date/Time: Thursday, May 4th, 2023, 11.00 am – 11.15 am CET

--- end of press release ---

About Medigene
Medigene AG (FSE: MDG1) is an immuno-oncology platform company dedicated to developing T cell therapies to effectively eliminate cancer. Its end-to-end technology platform is built on multiple proprietary product development and product enhancement technologies, and allows Medigene to create best-in-class differentiated, T cell receptor engineered T cell (TCR-T) therapies for multiple solid tumor indications that are optimized for both safety and efficacy. This platform provides product candidates for both its in-house therapeutics pipeline and partnering.
For more information, please visit

About Medigene’s End-To-End Platform
Medigene’s immunotherapies help activate the patient’s own defense mechanisms by harnessing T cells in the battle against cancer. Medigene’s end-to-end platform combines multiple exclusive and proprietary technologies to create best-in-class TCR-T therapies. The platform includes multiple product enhancement technologies, (e.g. PD1-41BB Switch Receptor, Precision Pairing) and development optimization technologies (e.g. Allogeneic-HLA (Allo-HLA) TCR Priming) to aid the development of differentiated TCR-T therapies. Partnerships with multiple companies including BioNTech, 2seventy bio, and Hongsheng Sciences, continue to validate the platform’s assets & technologies.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.


Pamela Keck
Phone: +49 89 2000 3333 01

LifeSci Advisors

Sandya von der Weid
Phone: +41 78 680 05 38

In case you no longer wish to receive any information about Medigene, please inform us by e-mail ( We will then delete your address from our distribution list.